Salih Ehsan: Bradykinin-Mediated Transfusion Reactions in Patients on ACE Inhibitors
Salih Ehsan, Chief Executive Officer at Kulsoom Society of Hematology, shared Caitlin Raymond’s post on LinkedIn:
“Thanks for this information.
When an anemic patient comes to a transfusion center, take a look on the drugs that patient is taking regularly (ACE inhibitors, diuretics).
If the patient is taking ACE inhibitors, be ready for hypotensive transfusion reaction in the middle of transfusion.
Correct measures are:
- stop transfusion
- watch for BP, pulse, respiration, oxygen saturation, temperature, subjective feeling of patient.
If everything is okay, except BP then go for IV fluids (volume expander like normal saline).”
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on LinkedIn:
“The transfusion reaction with the cleanest workup and the most interesting mechanism.
BP drops 40 points mid-transfusion.
No fever. No rash. No hemolysis.
DAT negative. Everything comes back normal.
This is a hypotensive transfusion reaction — and it’s not immunologic.
It’s pharmacologic.
Here’s what’s happening:
- Transfusion tubing and leukoreduction filters present a negatively charged surface to blood
- That contact activates Factor XII – kallikrein – bradykinin
- Bradykinin is a potent vasodilator with a half-life measured in seconds
- ACE normally clears it — but patients on ACE inhibitors can’t
- Result: bradykinin accumulates, vessels dilate, pressure drops
This is why ACE use is the most consistently identified risk factor for hypotensive transfusion reactions.
It’s not an allergy.
The drug is doing exactly what it was prescribed to do.
Management is straightforward: stop, fluids, recover.
No pre-medications indicated — Benadryl and acetaminophen do nothing for bradykinin-mediated hypotension.
The harder question is how many of these reactions we’re missing.
Hypotension is common in sick patients.
A modest BP dip in a patient on antihypertensives and diuretics may never trigger a workup.
New post on Blood Bytes Beyond.”
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 14:39Mona Alfaraj: Don’t Miss the Chance to Be Part of the 2nd International Hematology and Hemostasis Conference
-
Apr 23, 2026, 14:11Emerging Contributions to Hemostasis from Recipients of the Christine Lee Young Researcher Awards – WFH
-
Apr 23, 2026, 13:52Joffrey Feriel: A Revised ISTH Definition of Disseminated Intravascular Coagulation
-
Apr 23, 2026, 13:39Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation
-
Apr 23, 2026, 13:35Jecko Thachil: Risk Assessment and Clinical Management of Nephrotic Syndrome–Associated Thrombosis
-
Apr 23, 2026, 12:18Mona Ranade: A Contemporary Framework for Managing Right Heart Thrombus in PE
-
Apr 23, 2026, 11:59Strengthening Hemophilia Care Through Collaboration and Commitment in India at IHC X 2026 – Hemophilia Federation India
-
Apr 23, 2026, 08:16David Ferreira: Identifying the True Drivers of Recurrent Thrombosis
-
Apr 23, 2026, 08:05Hugo Antonio Romo Rubio: Biology, Function, and Updated Classification of von Willebrand Disease